Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · New England Journal of Medicine · 2006 · 2.6K citations · Full text

Medicine, Gynecology, Oncology +14

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

David S. Alberts, P. Y. Liu, Edward V. Hannigan et al. · New England Journal of Medicine · 1996 · 1.2K citations · Full text

Medicine, Oncology, Surgery +5

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

Maurie Markman, Brian N. Bundy, David S. Alberts et al. · Journal of Clinical Oncology · 2001 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +15

Clinical delivery system for intraperitoneal hyperthermic chemotherapy.

John S. Spratt, Robert A. Adcock, Marie Muskovin et al. · PubMed · 1980 · 481 citations

Medicine, Oncology, Surgery +12

Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

Maurie Markman, Pan Liu, Sharon P. Wilczynski et al. · Journal of Clinical Oncology · 2003 · 458 citations

Medicine, Oncology, Pharmacotherapy +13